Healthcare advances across the globe have increased life expectancy, facilitating increases in the prevalence of neurodegenerative diseases such as Alzheimer's disease (AD).1,2 In Canada for example, ca. 5% of the population over 65 years of age have AD, increasing to 25% over the age of 85 years old.3 Currently, there are no approved disease-modifying therapeutic interventions other than symptomatic treatments such as cholinesterase inhibitors.4 Here, BCHE is linked to Alzheimer disease.